NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 165 filers reported holding NEKTAR THERAPEUTICS in Q4 2014. The put-call ratio across all filers is 0.54 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2015 | $1,889,000 | -56.0% | 172,306 | -49.9% | 0.89% | -36.3% |
| Q2 2015 | $4,298,000 | -33.7% | 343,670 | -41.7% | 1.39% | -11.0% |
| Q1 2015 | $6,479,000 | +19.9% | 589,260 | +69.1% | 1.56% | +9.9% |
| Q4 2014 | $5,402,000 | +94.9% | 348,419 | +51.8% | 1.42% | +43.8% |
| Q3 2014 | $2,772,000 | – | 229,577 | – | 0.99% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 2,000,000 | $67,200,000 | 3.35% |
| First Light Asset Management, LLC | 763,403 | $25,650,000 | 3.33% |
| BRIDGER MANAGEMENT, LLC | 1,238,489 | $41,613,000 | 3.29% |
| Rhenman & Partners Asset Management AB | 734,445 | $24,677,000 | 2.89% |
| BB BIOTECH AG | 2,020,676 | $67,895,000 | 1.71% |
| Gs Investments, Inc. | 54,200 | $1,821,120,000 | 1.43% |
| Artal Group S.A. | 900,000 | $30,240,000 | 1.24% |
| Cormorant Asset Management, LP | 500,000 | $16,800,000 | 1.14% |
| TOBAM | 640,547 | $21,522,000 | 1.09% |
| Bellevue Group AG | 430,026 | $14,449,000 | 0.80% |